

daytime symptoms that often result from sleep disorders, such as narcolepsy and obstructive sleep apnea, in patients with insomnia. Each item on the AIS was rated from 0 (*no problem at all*) to 3 (*very serious problem*). Total scores can range from 0 to 24, with scores  $\geq 6$  and  $< 6$  representing the presence and absence of insomnia, respectively. This cutoff point had a sensitivity of 93 %, a specificity of 85 % (90 % overall correct case identification), a positive predictive value (PPV) of 41 % and a negative predictive value (NPV) of 99 % [27].

Responders were asked to calculate their scores if they had experienced sleep difficulties at least three times a week during the previous month.

#### Liver histology

All enrolled patients underwent a percutaneous liver biopsy under ultrasonic guidance or peritoneoscopy. The

liver specimens were embedded in paraffin and stained with hematoxylin and eosin, Masson-trichrome, reticulin silver stain, and Perls' Prussian blue. The specimens were evaluated by two hepatic pathologists (S.T. and Y.S.), who were blinded to the clinical findings. An adequate liver biopsy sample was defined as a specimen of length  $> 1.5$  cm and/or having more than 6 portal tracts. NASH was defined as steatosis with lobular inflammation and ballooning degeneration, with or without Mallory–Denk body or fibrosis. Patients with liver biopsy specimens showing simple steatosis or steatosis with nonspecific inflammation were identified as the NAFL cohort [28]. Specimens with steatosis of  $< 5$ ,  $5$ – $33$ ,  $> 33$ – $66$ , and  $> 66$  % were scored as having steatosis grades of 0, 1, 2, and 3, respectively [29]. Histological grade and stage were scored as described [30]. Necroinflammatory grades of 1, 2, and 3, were defined as mild, moderate and severe hepatocellular steatosis,

**Table 2** Clinical characteristics of enrolled patients with NAFL and NASH

Clinical parameter	Total ( $n = 123$ [100 %])	NAFL ( $n = 40$ [33 %])	NASH ( $n = 83$ [67 %])	<i>P</i> value
Age (years)	59 (14–82)	56 (20–78)	62 (14–82)	0.0025
Gender (female)	76 (62 %)	17 (43 %)	59 (71 %)	0.0030
BMI ( $\text{kg}/\text{m}^2$ )	26.6 (16.6–43.4)	26.6 (18.9–43.4)	27.3 (16.6–41.0)	0.1405
Obesity (BMI $> 25$ )	87 (71 %)	27 (68 %)	60 (72 %)	0.6731
Dyslipidemia (yes [%])	46 (37 %)	12 (30 %)	34 (41 %)	0.3202
Hypertension (yes [%])	48 (39 %)	10 (25 %)	38 (46 %)	0.0310
Type 2 diabetes (yes [%])	55 (45 %)	13 (33 %)	42 (51 %)	0.0811
Hemoglobin (g/dl)	14.1 (10.5–18.3)	14.8 (10.6–18.3)	13.8 (10.5–16.7)	0.0728
Platelet count ( $\times 10^4/\mu\text{l}$ )	21.4 (4.6–78.5)	23.5 (13.0–78.5)	20.8 (4.6–45.4)	0.0125
AST (IU/l)	45 (17–186)	37 (17–151)	51 (18–186)	0.0001
ALT (IU/l)	69 (12–358)	61 (15–358)	71 (12–218)	0.2425
GGT (IU/l)	61 (20–391)	60 (20–319)	62 (21–391)	0.6382
Cholinesterase (IU/l)	371 (167–547)	378 (266–545)	370 (167–547)	0.2873
Total cholesterol (mg/dl)	209 (87–335)	218 (127–335)	203 (87–319)	0.0183
Triglyceride (mg/dl)	156 (61–659)	155 (61–416)	162 (66–659)	0.4849
HDL-C (mg/dl)	50 (23–290)	49 (31–77)	52 (23–290)	0.7727
Ferritin (ng/ml)	163 (5–1100)	113 (10–1100)	210 (5–923)	0.0160
FPG (mg/dl)	96 (60–452)	96 (60–161)	96 (60–452)	0.3571
IRI ( $\mu\text{U}/\text{ml}$ )	11.4 (1.59–49.5)	8.4 (1.6–46)	13.2 (2.8–49.5)	$< 0.0001$
HOMA-IR	2.62 (0.38–33.04)	1.87 (0.38–13.63)	3.02 (0.65–33.04)	$< 0.0001$
Hyaluronic acid (ng/ml)	37 (9–3480)	22 (9–149)	49 (9–3480)	0.0001
Type IV collagen 7S (ng/ml)	4.5 (2.7–13)	3.7 (2.8–7.1)	5.1 (2.7–13.0)	$< 0.0001$
FSSG	4 (0–38)	4 (0–29)	3 (0–38)	0.5009
FSSG $\geq 8$ ( $n$ [%])	31 [25 %]	10 [25 %]	21 [25 %]	1.0000
AIS	3 (0–15)	3 (0–12)	4 (0–15)	0.5591
AIS $\geq 6$ ( $n$ [%])	34 [28 %]	10 [25 %]	24 [29 %]	0.8299

Results are presented as numbers with percentages in parenthesis for qualitative data or as mean  $\pm$  SD for quantitative data

BMI body mass index, AST aspartate aminotransferase, ALT alanine aminotransferase, GGT gamma glutamyl transpeptidase, FPG fasting plasma glucose, IRI immuno-reactive insulin

*P* values were calculated by *t* test or  $\chi^2$  analysis

ballooning and inflammation (acinar and portal), respectively. The severity of hepatic fibrosis (stage) was scored as: stage 1, zone 3 perisinusoidal fibrosis; stage 2, zone 3 perisinusoidal fibrosis with portal fibrosis; stage 3, zone 3 perisinusoidal fibrosis and portal fibrosis with bridging fibrosis; and stage 4, cirrhosis.

Treatment with RPZ

Thirteen NAFLD patients with GERD symptoms (11 females and 2 males) were administered 10 mg/day RPZ for 12 weeks. These patients completed both the FSSG and AIS before and after RPZ treatment.

Statistical analysis

Quantitative results are presented as medians and ranges, and qualitative results as numbers and percentages. Statistical differences in quantitative data were determined using the Mann–Whitney *U* test or Wilcoxon rank-sum test, and differences in qualitative data using Fisher’s exact probability test or  $\chi^2$  analysis (Tables 2, 4, 5; Figs. 1, 2, 3, 4). Correlations were calculated by Spearman rank correlation analysis (Table 3). Multivariate logistic regression analysis was used to identify variables independently associated with the occurrence of insomnia (Table 6). Statistical significance was defined as a *P* value < 0.05.

Results


Characteristics of study subjects

Table 2 summarizes the clinical and laboratory data of the patient population. Of the 123 patients with NAFLD, 76 (62 %) were female, and 87 (71 %) were obese (BMI > 25 kg/m<sup>2</sup>). Histologically, 83 patients (67 %) were diagnosed with NASH, and 40 (33 %) with NAFL. Patients with NASH were significantly older; were more predominantly female; were more likely to have hypertension and type 2 diabetes; had lower platelet counts and total cholesterol concentrations; and had higher levels of AST, ferritin, IRI, HOMA-IR, hyaluronic acid, and type IV collagen 7S. Of the 83 patients with NASH, 41 (49 %), 22 (27 %), 13 (16 %), and 7 (8 %) had stage 0–1, 2, 3, and 4 fibrosis, respectively.


Comparisons between NASH and NAFL

The distribution of AIS scores in patients with NAFL and NASH is shown in Fig. 1. Overall, 34 of the 123 patients (28 %) with NAFLD had AIS scores  $\geq 6$ , diagnostic of insomnia, including 10 of 40 (25 %) patients with NAFL and 24 of 83 (29 %) with NASH (*P* = 0.8299). Males and females had similar median AIS scores [3 (range 0–13) vs. 3 (range 0–15), *P* = 0.7954] and a similar prevalence of insomnia [26 % (12/47) vs. 29 % (22/76), *P* = 0.8359].


Fig. 1 The distribution of Athens Insomnia scale (AIS)




**Fig. 2** Correlation between FSSG and AIS. A significant positive correlation was found between AIS and FSSG



**Fig. 3** Relationship between AIS and histological findings. The box represents the interquartile ranges (25 and 75 %) from the median (horizontal line). The bars indicate the 10 and 90 %



**Fig. 4** Effects of rabeprazole (RPZ) on the improvement of GERD symptoms and insomnia. The box represents the interquartile ranges (25 and 75 %) from the median (horizontal line). The bars indicate the 10 and 90 %. **a** Change in the total FSSG score. RPZ significantly reduced total FSSG scores. \* $P = 0.0071$  compared to baseline response before treatment. **b** Change in the total AIS. RPZ significantly reduced total AIS. \* $P = 0.0144$  compared to baseline response before treatment



**Table 3** Correlation between AIS/FSSG and clinical parameters in 123 patients with biopsy-proven NAFLD

Variables	AIS		FSSG	
	Correlation coefficient	<i>P</i> value	Correlation coefficient	<i>P</i> value
Age	-0.0431	0.6363	-0.2363	0.0085
BMI	-0.0075	0.9345	0.091	0.3128
Hemoglobin	0.0104	0.9100	0.0328	0.7220
Platelet	0.1079	0.2407	0.2197	0.0159
AST	0.0588	0.5197	0.0015	0.9868
ALT	0.0284	0.7558	0.1148	0.2080
AST/ALT ratio	-0.0046	0.9597	-0.1254	0.1689
$\gamma$ GT	0.1545	0.0935	-0.1272	0.1681
Cholinesterase	0.1366	0.1646	0.1683	0.0861
Prothrombin time	0.0359	0.6998	0.1403	0.1296
Cholesterol	0.1366	0.7233	0.0624	0.5039
Triglyceride	-0.0343	0.7132	0.0506	0.5879
HDL-C	-0.0128	0.8943	-0.1166	0.2230
FPG	0.0442	0.6316	-0.2010	0.0277
IRI	-0.1073	0.2412	-0.1570	0.0855
HOMA-IR	-0.0993	0.2806	-0.1948	0.0330
Ferritin	0.0934	0.3081	-0.0490	0.5932
Hyaluronic acid	-0.0340	0.7088	-0.2246	0.0125
Type IV collagen 7S	-0.0193	0.8323	-0.1277	0.1592
FSSG	0.4108	<0.0001	-	-

*P* values are based on Spearman's non-parametric correlation analysis

FSSG scored did not differ in NAFL and NASH patients, with the prevalence of GERD being 25 % in each group.

#### Factors positively correlating with AIS and FSSG scores

AIS score was positively correlated with FSSG score ( $r = 0.4108$ ,  $P < 0.001$ ) (Fig. 2), but not with any other parameter (Table 3). FSSG score was positively correlated with platelet count ( $r = 0.2197$ ,  $P = 0.0159$ ), and negatively correlated with age ( $r = -0.2363$ ,  $P = 0.0085$ ), FPG concentration ( $r = -0.2010$ ,  $P = 0.0277$ ), HOMA-IR score ( $r = -0.1948$ ,  $P = 0.0330$ ) and hyaluronic acid concentration ( $r = -0.2246$ ,  $P = 0.0125$ ). BMI, transaminase activities, lipid profiles, and iron parameters were not correlated with AIS or FSSG score.

#### Correlation between histological findings and AIS scores

Assessment of histological findings in the 123 patients with NAFLD showed that 53 (43 %), 40 (33 %), and 30 (24 %) had steatosis grades 1, 2, and 3, respectively; 30 (24 %), 70 (57 %), 18 (15 %), and 5 (4 %) had inflammation grades 0,

1, 2, and 3, respectively; and 44 (36 %), 38 (31 %), 21 (17 %), 13 (11 %), and 7 (6 %) had fibrosis grades 0, 1, 2, 3, and 4, respectively. Evaluation of correlations between AIS scores and histological findings showed that AIS score was not correlated with steatosis, inflammation, or fibrosis grade (Fig. 3).

#### Clinical findings in patients with and without insomnia

Comparisons of clinical and laboratory findings in patients with and without insomnia showed that  $\gamma$ GT concentrations and FSSG scores were higher, and the prevalence of hypertension and IRI and HOMA-IR scores were lower, in patients with insomnia (Table 4). Moreover, GERD symptoms were significantly more prevalent in patients with than without insomnia (56 vs. 13 %,  $P < 0.0001$ ).

#### Drug usage

Drug usage in patients involved in this study was shown in Table 5. Beta-blockers users were more prevalent in patients with GERD compared to those without. The prevalence of other drug users was not different between patients with GERD/insomnia and those without.

**Table 4** The comparison between insomniacs and non-insomniacs

Clinical parameter	Insomniacs ( $n = 34$ [28 %])	Non-insomniacs ( $n = 89$ [72 %])	<i>P</i> value
Age (years)	56 (35–74)	60 (14–82)	0.8100
Gender (female)	22 (65 %)	54 (61 %)	0.8359
BMI ( $\text{kg}/\text{m}^2$ )	26.4 (21.9–38.6)	26.6 (16.6–43.4)	0.5028
Obesity (BMI > 25)	25 (74 %)	62 (70 %)	0.8252
Dyslipidemia	21 (62 %)	56 (63 %)	1.0000
Hypertension (yes)	8 (24 %)	40 (45 %)	0.0385
Type 2 diabetes (yes)	16 (47 %)	39 (44 %)	0.8400
Hemoglobin (g/dl)	14.4 (11.0–18.3)	14.0 (10.5–17.1)	0.9072
Platelet count ( $\times 10^4/\mu\text{l}$ )	22.3 (8.7–33.5)	21.1 (4.6–78.5)	0.7137
AST (IU/l)	47 (20–182)	44 (17–186)	0.4682
ALT (IU/l)	71 (12–358)	69 (15–218)	0.6233
GGT (IU/l)	77 (24–391)	59 (20–268)	0.0063
Cholinesterase (IU/l)	373 (208–547)	371 (167–545)	0.7992
Total cholesterol (mg/dl)	206 (125–314)	214 (87–335)	0.3670
Triglyceride (mg/dl)	146 (68–424)	164 (61–659)	0.3864
Ferritin (ng/ml)	128 (11–1100)	170 (5–923)	0.7315
FPG (mg/dl)	94 (70–452)	97 (60–171)	0.7708
IRI ( $\mu\text{U}/\text{ml}$ )	9.8 (2.8–11.2)	12.0 (1.6–49.5)	0.0326
HOMA-IR	2.10 (0.65–33.04)	2.96 (0.38–16.34)	0.0335
Hyaluronic acid (ng/ml)	32 (9–392)	37 (9–3480)	0.9774
Type IV collagen 7S (ng/ml)	4.7 (2.7–13.0)	4.4 (2.8–10.0)	0.9054
FSSG	8 (0–38)	3 (0–17)	<0.0001
FSSG $\geq 8$ ( $n$ [%])	19 [56 %]	12 [13 %]	<0.0001
NASH ( $n$ [%])	24 [71 %]	59 [66 %]	0.8299

Results are presented as numbers with percentages in parenthesis for qualitative data or as mean  $\pm$  SD for quantitative data

BMI body mass index, AST aspartate aminotransferase, ALT alanine aminotransferase, GGT gamma glutamyl transpeptidase, FPG fasting plasma glucose, IRI immuno-reactive insulin

*P* values were calculated by *t* test or  $\chi^2$  analysis

**Table 5** Drug usage

Drug usage	FSSG < 8 (n = 92)	FSSG ≥ 8 (n = 31)	P value	Insomniacs (n = 34)	Non-insomniacs (n = 89)	P value
Use of antihypertensive drugs						
Calcium antagonists	26 [28 %]	10 [32 %]	0.6560	7 [21 %]	29 [33 %]	0.2680
ARBs	4 [4 %]	2 [6 %]	0.6412	2 [6 %]	4 [4 %]	0.6679
Beta-blockers	2 [2 %]	4 [13 %]	0.0348	2 [6 %]	4 [4 %]	0.6679
Use of NSAIDs	10 [11 %]	2 [6 %]	0.7285	1 [3 %]	11 [12 %]	0.1762
Use of anticoagulants	2 [2 %]	0 [0 %]	1.0000	0 [0 %]	2 [2 %]	1.0000
Use of digestive drugs	2 [2 %]	0 [0 %]	1.0000	0 [0 %]	2 [2 %]	1.0000

ARBs angiotensin receptor blockers, NSAIDs non-steroidal anti-inflammatory drugs

**Table 6** Results of multivariate analysis: independent predictors of insomniacs

Variables	Adjusted (multivariate)		
	OR	95 % CI	P value
FSSG	1.2315	1.1221–1.3516	<0.0001
GGT	1.0109	1.0031–1.0189	0.0063
IRI	0.9515	0.8908–1.0164	0.1396
Hypertension	0.5503	0.1823–1.6610	0.2893

OR odds ratio, CI confidence interval, FSSG frequency scale for the symptoms of GERD, GGT gamma glutamyl transpeptidase, IRI immuno-reactive insulin

#### Factors independently predictive of insomnia in patients with NAFLD

Multivariate logistic regression analysis showed that plasma GGT concentration [odds ratio (OR) 1.2315, 95 % confidence interval (CI) 1.1221–1.3516,  $P < 0.0001$ ] and FSSG score (OR 1.0109, 95 % CI 1.0031–1.0189,  $P = 0.0063$ ) were significant independent predictors of insomnia (Table 6). In contrast, IRI and HOMA-IR scores and hypertension were not predictive.

#### Effects of RPZ on insomnia

RPZ treatment of patients with GERD significantly reduced FSSG and AIS scores (Fig. 4). Of the 9 patients with insomnia treated with RPZ, 4 (44 %) showed resolution of insomnia after treatment.

## Discussion

This study of Japanese NAFLD patients demonstrated that (1) 28 % had AIS scores  $\geq 6$ , indicative of insomnia; (2) 25 % had FSSG scores  $\geq 8$ , indicative of GERD; (3) AIS and FSSG scores did not differ significantly in patients

with NASH and NAFL; (4) FSSG score was independently associated with AIS score; and (5) insomnia could be relieved after treatment with RPZ.

The precise prevalence of insomnia in NAFLD patients has been unclear. Using the AIS, we found that 28 % of patients with biopsy-proven NAFLD had insomnia. Although sleep dysfunction has been defined as a Pittsburgh Sleep Quality Index (PSQI) score  $> 5.5$  in other studies [17, 31], the AIS is satisfactorily validated, simple to perform, and well accepted based on ICD-10 criteria. The AIS has been used to assess insomnia in the general population in Japan. For example, a study of approximately 3000 individuals found that 21.4 % had experienced insomnia during the previous month [32]. The prevalence of insomnia in our NAFLD patients does not seem to be markedly different from that in the general population. Though this precise reason is unknown, one plausible explanation is that about 20–30 % of the general population is estimated to have NAFLD. We should obtain data from sex- and age-matched non-NAFLD population to clarify whether the prevalence of insomnia in NAFLD is really higher compared to that in the general population. Assessments of employees of two local governments in Japan found that 1382 of 5951 males (23.2 %) and 465 of 1500 females (31.0 %), aged 34–59 years, had insomnia [33, 34]. Assessments of middle-aged women found that 27.5–43.6 % had AIS scores  $\geq 6$  [35, 36]. Taken together, these findings indicate that the prevalence of insomnia is higher in women than in men, across countries and cultures. In contrast, we observed no differences in AIS scores between men and women with NAFLD. Since the discrepancy between our results and previous studies can be explained by a small number of patients involved in this study, a larger number of patients should be examined in the future. Since Yoshioka et al. [34] showed that the gender difference disappeared after adjustment for paid work and family responsibilities, detailed characteristics of patients should be considered to clarify the gender differences. In Japanese studies in which insomnia was

diagnosed using AIS, factors associated with insomnia included work at visual display terminals for  $\geq 6$  h per day [37], job stress [38, 39], and reduced illumination in the workplace [40]. In this study, however, we did not evaluate these work environmental factors.

The mechanisms by which insomnia arises in patients with NAFLD have never been clarified. We found that AIS scores and the incidence of insomnia were similar in patients with NAFL and NASH. AIS scores did not correlate with any histological findings, such as steatosis, inflammation, and fibrosis scores, indicating that histological severity is not important in the pathogenesis of insomnia in patients with NAFLD. In contrast, many studies have explored the associations between life-style related disorders/obesity and sleep disturbance. Changes in secretion of the hormones cortisol, leptin, and ghrelin, and increased insulin resistance due to short sleep duration were found to increase the risks of obesity and diabetes [41–43]. In contrast, insomniacs were more likely to have insulin resistance than non-insomniacs. This study demonstrated that FSSG score was significantly correlated only with AIS score. Multivariate analysis showed that FSSG was an independent risk factor associated with insomnia, suggesting that GERD symptoms are responsible for insomnia in NAFLD patients, findings consistent with previously reported results [9, 17]. For example, sleep disorders, such as inability to sleep, difficult falling asleep, and awakening during the night, were observed in 56.3 % of patients with heartburn [9]. Similarly, we found that 61.3 % (19/31) of NAFLD patients with GERD had insomnia. A study in 134 Japanese patients with GERD found that FSSG score was significantly positively correlated with PSQI score [11]. GERD can affect sleep through two primary mechanisms. First, nighttime reflux, which occurs in 47–79 % of patients with GERD, can cause awakening during the night. Second, GERD can cause short, amnesic arousals (approximately 30 s), resulting in sleep fragmentation. However, recent studies also suggested that the link between GERD and sleep problems may be bidirectional. Sleep stage may influence the esophago-upper esophageal sphincter contractile reflex [44]. Sleep disturbance may reinforce the perception of intra-esophageal acid [45]. The association of NAFLD with GERD has been assessed in only two studies, which reported that 37 and 51 % of patients with NAFLD had GERD symptoms [7, 8], percentages higher than observed in the present study. Plausible explanations of a lower prevalence (25 %) of GERD in our NAFLD patients were the difference of ethics, sex/age distribution, and the diagnostic method of GERD or NAFLD between previous studies [7, 8] and ours. Another explanation is the possibility that our NAFLD patients receiving dietary

educations might avoid irregular diet habits, which are known to be the most significant risk factors for GERD symptoms [15]. In the future, sex- and age-matched controlled studies using a larger population is essential to draw conclusions. A recent study of Japanese patients with NAFLD found that GERD symptoms were significantly more severe in the group with higher than lower total cholesterol (T-CHO) and triglyceride (TG) levels [7]. In contrast, we observed no correlation between GERD symptoms and either T-CHO or TG. These conflicting results may be due to our inclusion of only patients with biopsy-proven NAFLD, who are not representative of the general population of patients diagnosed with NAFLD. In contrast, the patients included in the previous study were diagnosed with NAFLD by ultrasound [7]. Moreover, that study did not assess the association of insomnia with GERD symptoms. Thus, to our knowledge, our study is the first to clarify the relationship between insomnia and GERD symptoms in patients with NAFLD.

Previous studies suggested that acid suppression can improve sleep problems in GERD patients. For example, a prospective randomized clinical trial found that a significantly higher percentage of patients treated with esomeprazole than placebo showed resolution of GERD-related sleep disturbances [46]. RPZ treatment also significantly improved subjective indices of sleep quality over placebo [16]. Moreover, an 8-week course of RPZ treatment significantly decreased both FSSG and PSQI scores in Japanese patients [11]. Consistent with these findings, we found that treatment with RPZ significantly decreased both AIS and FSSG scores. These results also indicate that GERD symptoms are at least partly responsible for the occurrence of insomnia in NAFLD patients.

In addition to AIS score, GGT concentration was found to be an independent predictor of insomnia in patients with NAFLD. Serum GGT activity is a marker of oxidative stress [47]. The primary function of GGT is to maintain intracellular concentrations of glutathione, a critical antioxidant molecule. Thus, increased GGT activity can be regarded as a response to oxidative stress, aimed at increasing the intracellular concentration of glutathione. Although little is known about the relationship between insomnia and oxidative stress, a preliminary study showed that anti-oxidant activity was significantly lower and lipid peroxidation levels significantly higher in patients with primary insomnia than in controls [48]. Serum concentrations of GGT and 8-hydroxydeoxyguanosine are correlated in patients with NAFLD, indicating the occurrence of oxidative stress [49]. GGT has also been associated with the occurrence of metabolic syndrome, early atherosclerosis, and cardiovascular events [50]. Moreover, GGT concentrations are higher in patients with obstructive sleep

apnea syndrome (OSAS) than in controls [51] and have been associated with nocturnal arterial oxygen desaturation. Furthermore, continuous positive airway pressure treatment has been shown to decrease GGT, further suggesting that the increase in GGT is directly associated with OSAS. OSAS has also been associated with the presence and severity of NAFLD [52], suggesting that insomnia in patients with NAFLD is at least partly associated with the occurrence of OSAS. Our finding, that elevated GGT is an independent predictor of insomnia, suggests that these patients also have OSAS, although this was not directly evaluated in our patient population.

This study had several limitations. First, its design was cross-sectional, making it difficult to establish a cause-effect relationship, and suggesting the need for prospective studies. Second, the AIS is a self-administered questionnaire and subjective measure of insomnia, suggesting the need for assessment of objective sleep variables such as those obtained during polysomnography. Third, GERD was diagnosed based on FSSG scores alone, without endoscopic examination or 24 h pH monitoring. Because all participants were Japanese, there is a possibility that our results may not be applicable for NAFLD patients of other races or ethnic groups. The current study also did not assess the effects of smoking habits, mental status, dietary habit, and work environments. Additional studies, in larger populations, are needed to assess these variables.

In conclusion, we found that about 30 % of Japanese patients with biopsy-proven NAFLD have insomnia. GERD symptoms may be important in the development of insomnia. PPIs may be clinically useful for treating insomnia in NAFLD patients.

**Conflict of interest** Yuichiro Eguchi received a research grant from Bristol-Myers Squibb. Yoshito Itoh received commercial research funds from Dainippon Sumitomo Pharma Co., Ltd.

## References

- Angulo P. Nonalcoholic fatty liver disease. *N Engl J Med*. 2002;346:1221–31.
- Ludwig J, Viggiano TR, McGill DB, Oh BJ. Non-alcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease. *Mayo Clin Proc*. 1980;55:434–8.
- David K, Kowdley KV, Unalp A, Kanwal F, Brunt EM, Schwimmer JB. Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the nonalcoholic steatohepatitis clinical research network. *Hepatology*. 2009;49:1904–12.
- Kim CW, Yun KE, Jung HS, Chang Y, Choi ES, Kwon MJ, et al. Sleep duration and quality in relation to non-alcoholic fatty liver disease in middle-aged workers and their spouses. *J Hepatol*. 2013;59(2):351–7.
- Hsieh SD, Muto T, Murase T, Tsuji H, Arase Y. Association of short sleep duration with obesity, diabetes, fatty liver and behavioral factors in Japanese men. *Intern Med*. 2011;50:2499–502.
- Dew MA, Hoch CC, Buysse DJ, Monk TH, Begley AE, Houck PR, et al. Healthy older adults' sleep predicts all-cause mortality at 4 to 19 years of follow-up. *Psychosom Med*. 2003;65:63–73.
- Fujikawa Y, Tominaga K, Fujii H, Machida H, Okazaki H, Yamagami H, et al. High prevalence of gastroesophageal reflux symptoms in patients with non-alcoholic fatty liver disease associated with serum levels of triglyceride and cholesterol but not simple visceral obesity. *Digestion*. 2012;86:228–37.
- Miele L, Cammarota G, Vero V, Racco S, Cefalo C, Marrone G, et al. Non-alcoholic fatty liver disease is associated with high prevalence of gastro-oesophageal reflux symptoms. *Dig Liver Dis*. 2012;44:1032–6.
- Kusano M, Kouzu T, Kawano T, Ohara S. Nationwide epidemiological study on gastroesophageal reflux disease and sleep disorders in the Japanese population. *J Gastroenterol*. 2008;43:833–41.
- Jansson C, Nordenstedt H, Wallander MA, Johansson S, Johnsen R, Hveem K, Lagergren J. A population-based study showing an association between gastroesophageal reflux disease and sleep problems. *Clin Gastroenterol Hepatol*. 2009;7:960–5.
- Fujiwara Y, Kohata Y, Kaji M, Nebiki H, Yamasaki T, Sasaki E, et al. Sleep dysfunction in Japanese patients with gastroesophageal reflux disease: prevalence, risk factors, and efficacy of rabeprazole. *Digestion*. 2010;81:135–41.
- Johnson DA. Gastroesophageal reflux disease and sleep disorders: a wake-up call for physicians and their patients. *Rev Gastroenterol Disord*. 2005;5(Suppl 2):S3–11.
- Mody R, Bolge SC, Kannan H, Fass R. Effects of gastroesophageal reflux disease on sleep and outcomes. *Clin Gastroenterol Hepatol*. 2009;7:953–9.
- Orr WC. Review article: sleep-related gastro-oesophageal reflux as a distinct clinical entity. *Aliment Pharmacol Ther*. 2010;31:47–56.
- Yamamichi N, Mochizuki S, Asada-Hirayama I, Mikami-Matsuda R, Shimamoto T, Konno-Shimizu M, et al. Lifestyle factors affecting gastroesophageal reflux disease symptoms: a cross-sectional study of healthy 19864 adults using FSSG scores. *BMC Med*. 2012;10:45.
- Orr WC, Goodrich S, Robert J. The effect of acid suppression on sleep patterns and sleep-related gastro-oesophageal reflux. *Aliment Pharmacol Ther*. 2005;21:103–8.
- Fujiwara Y, Kohata Y, Kaji M, Nebiki H, Yamasaki T, Sasaki E, et al. Sleep dysfunction in Japanese patients with gastroesophageal reflux disease: prevalence, risk factors, and efficacy of rabeprazole. *Digestion*. 2010;81:135–41.
- Examination Committee of Criteria for 'Obesity Disease' in Japan; Japan Society for the Study of Obesity. New criteria for 'obesity disease' in Japan. *Circ J*. 2002;66:987–92.
- Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. *J Jpn diabetes Soc*. 2010;53:450–67.
- Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). *Hypertens Res*. 2009;32:3–107.
- Kusano M, Shimoyama Y, Sugimoto S, Kawamura O, Maeda M, Minashi K, Kuribayashi S, Higuchi T, Zai H, Ino K, Horikoshi T, Sugiyama T, Toki M, Ohwada T, Mori M. Development and evaluation of FSSG: frequency scale for the symptoms of GERD. *J Gastroenterol*. 2004;39:888–91.
- Yasaka S, Murakami K, Abe T, Anan J, Mizukami K, Tanahashi J, Okimoto T, Kodama M, Kudo Y, Kawasaki H, Fujioka T. Evaluation of esophageal function in patients with gastroesophageal reflux disease using transnasal endoscopy. *J Gastroenterol Hepatol*. 2009;24:1677–82.



23. Miyamoto M, Haruma K, Takeuchi K, Kuwabara M. Frequency scale for symptoms of gastroesophageal reflux disease predicts the need for addition of prokinetics to proton pump inhibitor therapy. *J Gastroenterol Hepatol*. 2008;23:746–51.
24. Furuta T, Shimatani T, Sugimoto M, Ishihara S, Fujiwara Y, Kusano M, et al. Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan. *J Gastroenterol*. 2011;46:1273–83.
25. Sakamoto Y, Inamori M, Iwasaki T, Lida H, Endo H, Hosono K, et al. Relationship between upper gastrointestinal symptoms and diet therapy: examination using frequency scale for the symptoms of gastroesophageal reflux disease. *Hepatogastroenterology*. 2010;57:1635–8.
26. Soldatos CR, Dikeos DG, Paparrigopoulos TJ. Athens Insomnia Scale: validation of an instrument based on ICD-10 criteria. *J Psychosom Res*. 2000;48:555–60.
27. Soldatos CR, Dikeos DG, Paparrigopoulos TJ. The diagnostic validity of the Athens Insomnia Scale. *J Psychosom Res*. 2003;55:263–7.
28. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver diseases: a spectrum of clinical and pathological severity. *Gastroenterology*. 1999;116:1413–9.
29. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Nonalcoholic Steatohepatitis Clinical Research Network, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. *Hepatology*. 2005;41:1313–21.
30. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. *Am J Gastroenterol*. 1999;94:2467–74.
31. Doi Y, Minowa M, Uchiyama M, Okawa M, Kim K, Shibui K, Kamei Y. Psychometric assessment of subjective sleep quality using the Japanese version of the Pittsburgh Sleep Quality Index (PSQI-J) in psychiatric disordered and control subjects. *Psychiatry Res*. 2000;97:165–72.
32. Kim K, Uchiyama M, Okawa M, Liu X, Ogihara R. An epidemiological study of insomnia among the Japanese general population. *Sleep*. 2000;23:41–7.
33. Yoshioka E, Saijo Y, Kita T, Satoh H, Kawaharada M, Kishi R. Effect of the interaction between employment level and psychosocial work environment on insomnia in male Japanese public service workers. *Int J Behav Med*. 2012. doi:10.1007/s12529-012-9230-9.
34. Yoshioka E, Saijo Y, Kita T, Satoh H, Kawaharada M, Fukui T, Kishi R. Gender differences in insomnia and the role of paid work and family responsibilities. *Soc Psychiatry Psychiatr Epidemiol*. 2012;47:651–62.
35. Monterrosa-Castro A, Marrugo-Flórez M, Romero-Pérez I, Chedraui P, Fernández-Alonso AM, Pérez-López FR. Prevalence of insomnia and related factors in a large mid-aged female Colombian sample. *Maturitas*. 2013;74:346–51.
36. Blümel JE, Cano A, Mezones-Holguín E, Barón G, Bencosme A, Benítez Z, et al. A multinational study of sleep disorders during female mid-life. *Maturitas*. 2012;72:359–66.
37. Yoshioka E, Saijo Y, Fukui T, Kawaharada M, Kishi R. Association between duration of daily visual display terminal work and insomnia among local government clerks in Japan. *Am J Ind Med*. 2008;51:148–56.
38. Utsugi M, Saijo Y, Yoshioka E, Horikawa N, Sato T, Gong Y, Kishi R. Relationships of occupational stress to insomnia and short sleep in Japanese workers. *Sleep*. 2005;28:728–35.
39. Nishitani N, Sakakibara H. Job stress factors, stress response, and social support in association with insomnia of Japanese male workers. *Ind Health*. 2010;48:178–84.
40. Kozaki T, Miura N, Takahashi M, Yasukouchi A. Effect of reduced illumination on insomnia in office workers. *J Occup Health*. 2012;54:331–5.
41. Spiegel K, Tasali E, Penev P, Van Cauter E. Brief communication: sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. *Ann Intern Med*. 2004;141:846–50.
42. Spiegel K, Leproult R, L'hermite-Balériaux M, Copinschi G, Penev PD, Van Cauter E. Leptin levels are dependent on sleep duration: relationships with sympathovagal balance, carbohydrate regulation, cortisol, and thyrotropin. *J Clin Endocrinol Metab*. 2004;89:5762–71.
43. Donga E, Van Dijk M, Van Dijk JG, Biermasz NR, Lammers GJ, van Kralingen KW, et al. A single night of partial sleep deprivation induces insulin resistance in multiple metabolic pathways. *J Clin Endocrinol*. 2010;95:2963–8.
44. Bajaj JS, Bajaj S, Dua KS, Jaradeh S, Rittmann T, Hofmann C, Shaker R. Influence of sleep stages on esophago-upper esophageal sphincter contractile reflex and secondary esophageal peristalsis. *Gastroenterology*. 2006;130:17–25.
45. Schey R, Dickman R, Parthasarathy S, Quan SF, Wendel C, Merchant J, et al. Sleep deprivation is hyperalgesic in patients with gastroesophageal reflux disease. *Gastroenterology*. 2007;133:1787–95.
46. Johnson DA, Orr WC, Crawley JA, Traxler B, McCullough J, Brown KA, Roth T. Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: a randomized, placebo-controlled trial. *Am J Gastroenterol*. 2005;100:1914–22.
47. Lee DH, Jacobs DR Jr. Serum gamma-glutamyltransferase: new insights about an old enzyme. *J Epidemiol Community Health*. 2009;63:884–6.
48. Gulec M, Ozkol H, Selvi Y, Tuluce Y, Aydin A, Besiroglu L, Ozdemir PG. Oxidative stress in patients with primary insomnia. *Prog Neuropsychopharmacol Biol Psychiatry*. 2012;37:247–51.
49. Irie M, Sohda T, Iwata K, Kunimoto H, Fukunaga A, Kuno S, et al. Levels of the oxidative stress marker  $\gamma$ -glutamyltranspeptidase at different stages of nonalcoholic fatty liver disease. *J Int Med Res*. 2012;40:924–33.
50. Kozakova M, Palombo C, Eng MP, Dekker J, Flyvbjerg A, Mitrakou A, et al. Fatty liver index, gamma-glutamyltransferase, and early carotid plaques. *Hepatology*. 2012;55:1406–15.
51. Barceló A, Barbé F, de la Peña M, Vila M, Pérez G, Piérola J, et al. Antioxidant status in patients with sleep apnoea and impact of continuous positive airway pressure treatment. *Eur Respir J*. 2006;27:756–60.
52. Musso G, Cassader M, Olivetti C, Rosina F, Carbone G, Gambino R. Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis. *Obes Rev*. 2013;14:417–31.

# Glycemic Variability Is an Independent Predictive Factor for Development of Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease

Motoi Hashiba<sup>1</sup>, Masafumi Ono<sup>1\*</sup>, Hideyuki Hyogo<sup>2</sup>, Yukio Ikeda<sup>3</sup>, Kosei Masuda<sup>1</sup>, Reiko Yoshioka<sup>1</sup>, Yoichi Ishikawa<sup>1</sup>, Yuri Nagata<sup>1</sup>, Kensuke Munekage<sup>1</sup>, Tsunehiro Ochi<sup>1</sup>, Akira Hirose<sup>1</sup>, Yasuko Nozaki-Fujimura<sup>1</sup>, Shuhei Noguchi<sup>4</sup>, Nobuto Okamoto<sup>1</sup>, Kazuaki Chayama<sup>2</sup>, Narufumi Suganuma<sup>4</sup>, Toshiji Saibara<sup>1</sup>

**1** Department of Gastroenterology and Hepatology, Kochi Medical School, Kochi, Japan, **2** Department of Medicine and Molecular Science, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan, **3** Diabetes Center, Kochi Memorial Hospital, Kochi, Japan, **4** Department of Environmental Medicine, Kochi Medical School, Kochi, Japan

## Abstract

Patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) often have metabolic disorders including insulin resistance and type 2 diabetes mellitus (T2DM). We clarified the predictive factors in glucose metabolism for progression of hepatic fibrosis in patients with NAFLD by the 75-g oral glucose tolerance test (75gOGTT) and a continuous glucose monitoring system (CGMS). One hundred sixty-nine patients (68 female and 101 male patients) with biopsy-proven NAFLD with performance with 75gOGTT were enrolled and divided into four groups according to the stage of hepatic fibrosis (F0–3). The proportion of patients with T2DM significantly gradually increased, HbA1c and the homeostasis model assessment of insulin resistance were significantly elevated, and 1,5-anhydroglucitol (1,5-AG) was remarkably decreased with the progression of fibrosis. In the 75gOGTT, both plasma glucose and insulin secretion were remarkably increased with the progression of fibrosis. The only factor significantly associated with advanced fibrosis was 1,5-AG ( $P=0.008$ ) as determined by multivariate logistic regression analysis. We next evaluated the changes in blood glucose during 24 hours by monitoring with the CGMS to confirm the relationship between glycemic variability and progression of fibrosis. Variability of median glucose, standard deviation of median glucose ( $P=0.0022$ ), maximum blood glucose ( $P=0.0019$ ), and  $\Delta\text{Min-max}$  blood glucose ( $P=0.0029$ ) were remarkably higher in severe fibrosis than in mild fibrosis.

**Conclusion:** Hyperinsulinemia and hyperglycemia, especially glycemic variability, are important predictive factors in glucose impairment for the progression of hepatic fibrosis in NAFLD.

**Citation:** Hashiba M, Ono M, Hyogo H, Ikeda Y, Masuda K, et al. (2013) Glycemic Variability Is an Independent Predictive Factor for Development of Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease. PLoS ONE 8(11): e76161. doi:10.1371/journal.pone.0076161

**Editor:** Manlio Vinciguerra, University College London, United Kingdom

**Received:** July 2, 2013; **Accepted:** August 20, 2013; **Published:** November 6, 2013

**Copyright:** © 2013 Hashiba et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** This work was supported by Grants-in-Aid for Scientific Research (C) 2011 Grant # 23590979, Ministry of Education, Culture, Sports, Science and Technology, Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have declared that no competing interests exist.

\* E-mail: onom@kochi-u.ac.jp


## Introduction

Nonalcoholic fatty liver disease (NAFLD) includes a wide spectrum of liver diseases that range from simple steatosis, which is usually a benign and non-progressive condition, to nonalcoholic steatohepatitis (NASH), which can progress to liver cirrhosis (LC) and hepatocellular carcinoma in the absence of significant alcohol consumption [1–3]. The progression of hepatic fibrosis is an important predictive factor for the development of LC and hepatocellular carcinoma not only in patients with chronic hepatitis C, but also in those with NASH [4]. To inhibit the progression of hepatic fibrosis in NASH, it is important to clarify the predictive factors for progression of hepatic fibrosis.

NASH and NAFLD are considered to be hepatic manifestations of the metabolic syndrome including insulin resistance (IR) and abnormalities of glucose metabolism [5,6]. In accordance

with the increased prevalence of obesity and type 2 diabetes mellitus (T2DM) in the general population worldwide, the number of patients with NASH and NAFLD have also increased [7,8]. T2DM is considered to be an independent risk factor for the development of NASH and NAFLD [9,10], and hyperinsulinemia and hyperglycemia are common not only in obese patients, but also in non-obese, non-diabetic patients with NASH [11]. On the other hand, the presence of NASH and NAFLD themselves is also considered to be associated with a high risk of developing T2DM [12].

Postprandial hyperglycemia and glycemic variability were reported to involve progression of atherosclerosis through increase of oxidative stress, activation of inflammatory cytokines and inflammation [13–15]. Oxidative stress is well known as one of most important factor for inflammation and progression of hepatic fibrosis in NAFLD patients [16,17]. The continuous glucose



**Figure 1. Relationship between glucose impairment and progression of hepatic fibrosis.** The frequencies of NGT, IGT/IFG, and T2DM in the four stages of hepatic fibrosis are shown. The diagnosis of glucose impairment was based on the 75gOGTT. The prevalence of NGT in patients in the F0 group (80.0%) was significantly higher than that in the F1 (43.2%), F2 (31.3%), and F3 groups (21.6%), and the frequencies of patients with T2DM in the F3 group (48.6%) was significantly higher than that in the F0 (0%), F1 (22.9%), and F2 (35.4%) groups. *P*-values were calculated using the  $\chi^2$ -test. Fibrosis stage (F): F0 (*n* = 10), F1 (*n* = 74), F2 (*n* = 48), F3 (*n* = 37); total, *N* = 169. doi:10.1371/journal.pone.0076161.g001

monitoring system (CGMS) has been introduced as a useful tool, which detect postprandial hyperglycemia [18] and glycemic variability during 24 hours in DM patients. In addition, episodic hypoglycemia during sleeping time can also be detected by CGMS [19]. However, postprandial hyperglycemia and glycemic variability have not yet been evaluated by CGMS in NAFLD patients. Moreover, the relationship between the clinical features of glucose impairment and the progression of hepatic fibrosis in NASH and NAFLD has not been well elucidated. In this study, therefore, we clarified the predictive factors in glucose metabolism for the progression of hepatic fibrosis in NAFLD using the 75-g oral glucose tolerance test (75gOGTT) and CGMS.

## Patients and Methods

### Patients

A total of 169 patients with biopsy-proven NAFLD (68 female and 101 male patients) with performance with 75gOGTT were enrolled in this study. Liver biopsies had been obtained in all patients after a thorough clinical evaluation had been performed and signed informed consent had been obtained from each patient. Patients with known use of methotrexate, tamoxifen, corticosteroids, or alcohol in excess of 20 g per day and patients with other known causes of liver disease including viral hepatitis, hemochromatosis, Wilson's disease, and autoimmune liver diseases were excluded from this study. None of the patients had received anti-diabetic drugs or insulin. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki [20] and was approved by the Research Committee of Kochi Medical School.

### Clinical and Laboratory Evaluation

Venous blood samples were obtained in the morning after a 12-hour overnight fast. Laboratory tests in all patients included measurements of serum aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transpeptidase, lipid profiles, total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, fasting plasma glucose, fasting

immunoreactive insulin (f-IRI), creatinine, blood urea nitrogen, 1,5-anhydroglucitol (1,5-AG), HbA1c, and fibrosis markers. These parameters were measured using standard clinical chemistry techniques in the laboratory section of Kochi Medical School Hospital. All patients underwent the 75gOGTT. Plasma glucose and insulin concentrations were measured at 0, 30, 60, 90, 120, and 180 minutes. Insulin resistance was calculated by the homeostasis model (HOMA)-IR using following formula:  $\text{HOMA-IR} = \text{fasting plasma insulin } (\mu\text{U/ml}) \times \text{fasting plasma glucose } (\text{mg/dl}) / 405$ . The measure of insulin secretion was calculated by the insulinogenic index using following formula:  $\text{insulinogenic index} = (\Delta\text{plasma insulin } 0\text{--}30 \text{ min}) / (\Delta\text{plasma glucose } 0\text{--}30 \text{ min})$ .

### Histological Evaluation

Liver biopsies of all patients were performed percutaneously under ultrasonographic guidance, and biopsy specimens were obtained from the liver parenchyma of the upper region of the right lobe using a 15-gauge biopsy needle. Liver biopsy specimens were routinely fixed in 10% phosphate-buffered formalin (pH 7.4), embedded in paraffin, and sectioned for hematoxylin and eosin staining. Hepatic fibrosis was assessed by Brunt's classification [21], and fibrosis staging was as follows: 0 = no fibrosis; 1 = zone 3 fibrosis only; 2 = zone 3 and portal/peripoportal fibrosis; 3 = bridging fibrosis; and 4 = cirrhosis. Histological evaluation was performed by two pathologists with no knowledge of the patients' clinical data.

### Continuous Glucose Monitoring System (CGMS)

Continuous glucose levels in 20 patients with biopsy-proven NAFLD were monitored by the CGMS System Gold (Medtronic MiniMed, Northridge, CA, USA). None of the patients had received anti-diabetic drugs, including insulin injection. In the severe hepatic fibrosis group, four patients with NAFLD with F4 fibrosis (LC) were included in this study, unlike in the 75gOGTT study. According to the operating guidelines, the CGMS was installed in the patients to monitor the glucose levels of interstitial fluid [22]. The glucose sensor was inserted into the subcutaneous tissue of the abdomen at 3:00 to 4:00 PM and was monitored for 30 hours. Finger-stick blood glucose levels were checked to calibrate the first glucose value of the CGMS after 1 hour of initialization. Glucose concentrations were determined at least four times per day with an automatic blood glucose meter (Glutest; Sanwa Kagaku Kenkyusho Co., Ltd., Nagoya, Japan). Meals were strictly standardized (1800 kcal/day of standard diets at Kochi Medical School Hospital) during the examination.

### Statistical Analyses

Results are presented as mean  $\pm$  standard deviation for quantitative data and as numbers or percentages for categorical or qualitative data. Statistical differences in quantitative data were determined using the Mann-Whitney U test or post-hoc test. Qualitative data were compared using the chi-square test. Multivariate analysis was carried out by logistic regression. These statistical analyses were carried out using Small Stata 10.1 for Windows. Results were considered significant when the *P* value was  $<0.05$ .

## Results

### Relationship between glucose impairment and progression of hepatic fibrosis

To investigate the relationship among clinical features of glucose levels, insulin secretion, and hepatic fibrosis, the 169

**Table 1.** Clinical and physiological characteristics of patients with NAFLD in the four stages of hepatic fibrosis.


	F0 (n = 10)		F1 (n = 74)		F2 (n = 48)		F3 (n = 37)	
Gender (F/M)	4/6		25/49		18/30		21/16	
Age (yo)	39.6	± 12.2	45.6	± 15.4	49.1	± 14.2	53.6	± 14.3***, ##
BMI (kg/m <sup>2</sup> )	27.4	± 3.0	27.6	± 5.5	28.3	± 4.3	30.1	± 4.6 ##
AST (IU/L)	37.8	± 11.1	43.4	± 20.9	54.5	± 32.8 #	79.3	± 46.1***, ##, ++
ALT (IU/L)	64.5	± 29.4	78.2	± 37.1	99.8	± 67.6 #	111.1	± 68.1*, #
ALP (IU/L)	207.2	± 109.9	240.8	± 109.8	287.8	± 100.7	253.1	± 106.3
GGT (IU/L)	113.6	± 101.3	58.2	± 42.9**	79.7	± 40.0	91.8	± 80.3 #
ChE (IU/L)	375.9	± 59.2	359.8	± 77.7	371.5	± 54.8	328.0	± 82.6
Albumin (g/dl)	4.44	± 0.22	4.58	± 0.28	4.45	± 0.28	4.45	± 0.31
BUN (mg/dl)	13.8	± 2.6	13.8	± 4.0	14.8	± 4.9	13.7	± 3.9
Crn (mg/dl)	0.69	± 0.11	0.84	± 0.97	0.66	± 0.22	0.68	± 0.12
UA (mg/dl)	6.38	± 1.70	6.42	± 2.21	6.38	± 1.29	5.85	± 1.08
FPG (mg/dl)	90.8	± 8.6	104.6	± 24.1	100.6	± 15.5	106.5	± 20.9 *
HbA1c (%)	5.46	± 0.22	5.92	± 1.14	5.96	± 0.77 *	6.27	± 0.98 *
T-Cho (mg/dl)	214.6	± 39.8	203.5	± 35.3	222.2	± 29.8 #	215.3	± 53.7 +
TG (mg/dl)	185.9	± 144.9	150.4	± 90.6	186.8	± 98.0 #	142.7	± 55.0 +
RBC (×10 <sup>6</sup> /ml)	467.0	± 49.5	478.9	± 49.0	446.4	± 38.9	445.1	± 38.2 #
Hb (g/dl)	14.1	± 1.4	14.3	± 1.8	13.9	± 1.6	13.9	± 0.8
Plt (×10 <sup>4</sup> /ml)	24.0	± 5.3	23.7	± 5.9	22.8	± 3.8 #	20.0	± 5.4 #, #
WBC (×10 <sup>3</sup> /ml)	4.47	± 3.18	5.29	± 2.54	5.42	± 2.64	4.02	± 3.10
Fe (mg/dl)	93.2	± 17.6	106.4	± 30.6	107.2	± 20.6	127.1	± 42.6 #
Ferritin (ng/ml)	155.7	± 131.0	241.7	± 172.9	262.9	± 192.6	328.3	± 277.2 #
HA (ng/ml)	20.2	± 13.5	30.4	± 19.5	34.1	± 26.3	93.5	± 105.0 ###, +++
IVcollagen7S (ng/ml)	2.79	± 0.52	3.52	± 0.67 **	3.77	± 1.01 **	5.05	± 2.35*, ##, ++
P-3-P (U/ml)	0.53	± 0.14	0.57	± 0.17	0.69	± 0.24	0.92	± 0.66 #

P-values were calculated using the Mann-Whitney U test. Versus F0: \*P<0.05, \*\*P<0.01, \*\*\*P<0.001. Versus F1: #P<0.05, ##P<0.01, ###P<0.001. Versus F2: \*\*P<0.01, \*\*\*P<0.001. Fibrosis stage (F): F0 (n = 10), F1 (n = 74), F2 (n = 48), F3 (n = 37); total, N = 169. BMI, body mass index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyl transpeptidase; ChE, cholinesterase; UA, uric acid; T-Cho, total cholesterol; TG, triglycerides; FPG, fasting plasma glucose; Plt, platelets; Fe, plasma iron; HA, hyaluronic acid; IV collagen 7S, type IV collagen 7S; P-3-P, type III procollagen N-peptide.  
doi:10.1371/journal.pone.0076161.t001


patients with NAFLD were classified into four groups based on the stage of hepatic fibrosis stage: F0 (n = 10), F1 (n = 74), F2 (n = 48), and F3 (n = 37). The clinical and physiological data of the four groups are shown in Table 1. The hepatic fibrosis markers hyaluronic acid, type IV collagen 7S, and type III procollagen N-peptide were significantly increased according to the progression of hepatic fibrosis. In addition, the patients with severe fibrosis were much older and had higher ferritin and transaminase levels. The platelet count tended to decrease according to the progression of hepatic fibrosis. We next evaluated the relationship between the prevalence of T2DM diagnosed by 75gOGTT and the stage of hepatic fibrosis in patients with NAFLD. The prevalence of patients with normal glucose tolerance (NGT) was 80%, and no patients with T2DM were found in the F0 group (Fig. 1). On the other hand, the prevalence of NGT in the patients with F3 disease was only 21.6%, and the prevalence of T2DM was 48.6%. In accordance with the progression of hepatic fibrosis, the prevalence of patients with T2DM was significantly gradually increased (F0 versus F2, P<0.05; F0 versus F3, P<0.01; F1 versus F3, P<0.05). To clarify the factors of glucose impairment that are related to the progression of hepatic fibrosis, we evaluated the various parameters of glucose metabolism.

Figure 2A shows that the patients with advanced hepatic fibrosis showed significantly higher levels of HbA1c (F0 versus F2, P<0.05; F0 versus F3, P<0.05). In addition, 1,5-AG was significantly decreased in accordance with the progression of hepatic fibrosis (F0 versus F2, P<0.05; F0 versus F3, P<0.0001; F1 versus F3, P<0.001; F2 versus F3, P<0.05) (Fig. 2B). Severe variability of plasma glucose levels might involve the progression of hepatic fibrosis. HOMA-IR was also elevated in the patients with advanced hepatic fibrosis (F0 versus F2, P<0.05; F0 versus F3, P<0.05; F1 versus F2, P<0.05; F1 versus F3, P<0.01) (Fig. 2C). On the other hand, although the insulinogenic index tended to decrease in accordance with the progression of hepatic fibrosis, no statistically significant difference was recognized in our study (Fig. 2D).

We next evaluated the patterns of glucose and insulin secretion by the 75gOGTT in patients with NAFLD. As shown in Figure 3A, not only the fasting glucose levels (F0 versus F3, P<0.05), but also the glucose levels after oral glucose loading (at 30, 60, 90, and 120 minutes) were significantly increased in parallel with the progression of fibrosis. The area under the curve (AUC) of the plasma glucose level (AUC-PG) as the marker for total glucose secretion after oral glucose loading also increased in accordance with the progression of hepatic fibrosis (F0 versus F2, P<0.05; F0



**Figure 2. Relationship between hepatic fibrosis and various parameters of glucose metabolism.** A) HbA1c was significantly elevated in accordance with the progression of hepatic fibrosis (F0 versus F2,  $*P < 0.05$ ; F0 versus F3,  $***P < 0.05$ ; N = 169). B) 1,5-Anhydroglucitol (1,5-AG) levels were remarkably decreased with the progression of hepatic fibrosis (F0 versus F2,  $*P < 0.05$ ; F0 versus F3,  $****P < 0.0001$ ; F1 versus F3,  $***P < 0.001$ ; F2 versus F3,  $*P < 0.05$ ; N = 169). C) HOMA-IR was significantly elevated in the patients with advanced hepatic fibrosis (F0 versus F2,  $*P < 0.05$ ; F0 versus F3,  $*P < 0.05$ ; F1 versus F2,  $*P < 0.05$ ; F1 versus F3,  $**P < 0.01$ ; N = 169). D) The insulinogenic index did not differ among the fibrosis groups (N = 169). doi:10.1371/journal.pone.0076161.g002



**Figure 3. Patterns of glucose and insulin secretion in the 75gOGTT in relation to the progression of hepatic fibrosis.** A) The glucose levels were significantly elevated in accordance with the progression of fibrosis (Versus F0:  $*P < 0.05$ ,  $***P < 0.01$ ; Versus F1:  $#P < 0.05$ ,  $###P < 0.001$ ; Versus F2:  $*P < 0.05$ ). B) Area under the curve (AUC) of plasma glucose levels (AUC-PG) was remarkably larger in accordance with the progression of hepatic fibrosis (F0 versus F2,  $*P < 0.05$ ; F0 versus F3,  $**P < 0.01$ ; F1 versus F3,  $#P < 0.05$ ; F2 versus F3,  $*P < 0.05$ ). C) Insulin secretion levels were remarkably higher in the patients with progression of hepatic fibrosis (Versus F0:  $*P < 0.05$ ,  $***P < 0.01$ ; Versus F1:  $#P < 0.05$ ,  $##P < 0.01$ ,  $###P < 0.001$ ). D) AUC of insulin secretion (AUC-IRI) was also significantly larger in accordance with the progression of hepatic fibrosis (F0 versus F3,  $*P < 0.05$ ; F1 versus F3,  $##P < 0.01$ ). (Black diamond: F0: n = 10. Gray square: F1: n = 74. Black triangle: F2: n = 48. Gray circle: F3: n = 37; total, N = 169). doi:10.1371/journal.pone.0076161.g003

**Table 2.** Comparison of the parameters of glucose metabolism between patients with mild fibrosis (F0–2) and severe fibrosis (F3).

	F0-2		F3		P value
	(n = 132)		(n = 37)		
<b>Gender (F/M)</b>	<b>47/85</b>		<b>21/16</b>		
Age (yo)	46.4	± 14.9	53.6	± 14.3	0.00967
BMI (kg/m <sup>2</sup> )	27.4	± 3.0	30.1	± 4.6	0.01395
FPG (mg/dl)	102.1	± 20.7	106.5	± 20.9	0.25665
HbA1c (%)	5.90	± 0.97	6.27	± 0.98	0.04520
f-IRI (μU/ml)	12.0	± 7.5	18.3	± 11.8	0.00012
HOMA-IR	2.98	± 1.92	4.14	± 2.47	0.00320
insulinogenic index	0.96	± 1.06	0.85	± 0.89	0.54574
AUC-IRI (10 <sup>3</sup> μU/ml/min)	12.9	± 8.3	18.4	± 9.2	0.00103
AUC-PG (10 <sup>3</sup> mg/dl/min)	29.6	± 10.0	34.3	± 9.5	0.01093
1,5-AG (μg/ml)	21.4	± 8.8	15.2	± 7.3	0.00014

P-values were calculated using the Mann–Whitney U test. Data are expressed as mean ± standard deviation. BMI, body mass index; FPG, fasting plasma glucose; f-IRI, fasting immunoreactive insulin; HOMA-IR, homeostasis model assessment of insulin resistance; AUC-IRI, area under the curve of IRI secretion; AUC-PG, area under the curve of plasma glucose; 1,5-AG, 1,5-anhydroglucitol. doi:10.1371/journal.pone.0076161.t002

versus F3,  $P < 0.01$ ; F1 versus F3,  $P < 0.05$ ; F2 versus F3,  $P < 0.05$ ) (Fig. 3B). In addition, f-IRI was significantly elevated in accordance with the progression of hepatic fibrosis (F0 versus F2,  $P < 0.05$ ; F0 versus F3,  $P < 0.05$ ; F1 versus F2,  $P < 0.05$ ; F1 versus F3,  $P < 0.001$ ) (Fig. 3C). Furthermore, the AUC of IRI secretion (AUC-IRI) was also significantly increased in accordance with the progression of hepatic fibrosis (F0 versus F3,  $P < 0.05$ ; F1 versus F3,  $P < 0.01$ ) (Fig. 3D). In particular, the insulin levels at 120 minutes were remarkably higher in the patients with advanced hepatic fibrosis (F0 versus F2,  $P < 0.05$ ; F0 versus F3,  $P < 0.01$ ; F1 versus F2,  $P < 0.01$ ; F1 versus F3,  $P < 0.01$ ). On the other hand, insulin secretion levels at 30 minutes were not statistically different among the groups.

To clarify the prognostic factors associated with advanced hepatic fibrosis, the factors that might be related to glucose metabolism were compared between the mild fibrosis group (F0–2) and severe fibrosis group (F3). Table 2 shows that age, body mass index, HbA1c, f-IRI, HOMA-IR, AUC-IRI, and AUC-PG were significantly higher in the F3 group than in the F0–2 group. Furthermore, 1,5-AG was significantly lower in the F3 group than in the F0–2 group ( $P = 0.00014$ ). In contrast, fasting plasma glucose and the insulinogenic index were not significantly different between these groups. As determined by multivariate logistic regression analysis, 1,5-AG ( $P = 0.008$ ; Z value,  $-2.65$ ; odds ratio [OR],  $0.89509$ ; 95% confidence interval [CI],  $0.82473–0.97145$ ) was the only independent factor for association of advanced hepatic fibrosis in patients with NAFLD (Table 3).

**Table 3.** Factors associated with progression of hepatic fibrosis in multivariate logistic regression analysis.


	Odds ratio	95% CI	Z value	P value
Age (yo)	1.04252	1.00009–1.08676	1.96	0.051
BMI (kg/m <sup>2</sup> )	1.08810	0.96010–1.23318	1.32	0.186
HbA1c (%)	0.82385	0.37798–1.79568	$-0.49$	0.626
f-IRI (μU/ml)	1.15005	0.89106–1.48432	1.07	0.283
HOMA-IR	0.81485	0.32819–2.02311	$-0.44$	0.659
insulinogenic index	0.59433	0.29955–1.17917	$-1.49$	0.137
AUC-IRI (10 <sup>3</sup> μU/ml/min)	1.00006	0.99997–1.00014	1.29	0.196
AUC-PG (10 <sup>3</sup> mg/dl/min)	1.00000	0.99989–1.00011	$-0.08$	0.937
1,5-AG (μg/ml)	0.89509	0.82473–0.97145	$-2.65$	0.008

P-values were calculated using logistic regression. BMI, body mass index; FPG, fasting plasma glucose; f-IRI, fasting immunoreactive insulin; HOMA-IR, homeostasis model assessment of insulin resistance; AUC-IRI, area under the curve of IRI secretion; AUC-PG, area under the curve of plasma glucose; 1,5-AG, 1,5-anhydroglucitol; CI, confidence interval. doi:10.1371/journal.pone.0076161.t003

### Continuous glucose monitoring system (CGMS) clarified that variability of glucose changes was associated with advanced hepatic fibrosis

In multivariate logistic regression analysis, 1,5-AG was selected as the independent associated factor for advanced hepatic fibrosis. A lower 1,5-AG might indicate not only poor control of plasma glucose, but also severe variability of plasma glucose changes. We hypothesized that severe variability of plasma glucose levels might involve the progression of hepatic fibrosis. To address our hypothesis, we investigated the variability of glucose levels during 24 hours by a CGMS. We used the CGMS for 10 patients in the severe fibrosis group (F3–4), including patients with LC, and 10 patients in the mild hepatic fibrosis group (F0–2). No patients in either group took any anti-diabetes drugs or insulin injections. The clinical data of both groups are shown in Table S1 in File S1.

The average median glucose level of the patients with mild fibrosis (F0–2) was significantly lower than that in the patients with severe fibrosis (F3–4) ( $108.1 \pm 12.1$  versus  $132.8 \pm 39.5$  mg/dl,  $P < 0.00001$ ) (Fig. 4 and Table 4). The variability of median glucose levels of the patients with mild fibrosis was remarkably smaller than that in the patients with severe fibrosis, as shown in Figure 4. The standard deviation of the median glucose levels in the patients with mild fibrosis was remarkably smaller than that in the patients with severe fibrosis ( $17.4 \pm 5.2$  versus  $39.7 \pm 17.8$  mg/dl,  $P = 0.0022$ ). In addition,  $\Delta$ Min–max blood glucose was also significantly larger in patients with severe fibrosis than in those with mild fibrosis ( $165.0 \pm 69.6$  versus  $115.2 \pm 22.8$  mg/dl,  $P = 0.0029$ ). Furthermore, all postprandial glucose levels (shaded areas in Fig. 4, from  $P < 0.05$  to  $P < 0.001$ ) and maximum glucose levels ( $P = 0.0019$ ) (Table 4) in the patients with severe fibrosis were significantly higher than those in the patients with mild fibrosis, although the minimum blood glucose levels were not significantly different ( $P = 0.9221$ ).



**Figure 4. Twenty-four-hour sensor glucose profiles by continuous glucose monitoring system.** The changes in the median sensor glucose levels during 24 hours are shown in the patients with A) mild fibrosis (F0–2,  $n = 10$ ) and B) severe fibrosis (F3–4,  $n = 10$ ). The variability of median glucose levels among the patients with mild fibrosis was remarkably smaller than that among the patients with severe fibrosis. Median glucose levels in the patients with severe fibrosis were higher than those with mild fibrosis (shadows areas,  $P < 0.05$  to  $P < 0.001$ ). Black diamond: Time of meal consumption.

doi:10.1371/journal.pone.0076161.g004

## Discussion

The number of patients with NAFLD and NASH has increased according to the increase in the prevalence of patients with obesity and T2DM worldwide. Patients with NAFLD and NASH often have metabolic disorders including IR and T2DM. In particular, IR is considered to be one of most important background factors for the development of NAFLD and NASH. However, detailed clinical features of impairment of glucose metabolism in patients with NAFLD and NASH are not well understood. In this study, we clarified the predictive factors in glucose metabolism for the development of hepatic fibrosis in patients with NAFLD by the 75gOGTT and CGMS methods.

We evaluated the relationship between the prevalence of T2DM diagnosed by the 75gOGTT and the degree of hepatic fibrosis in patients with NAFLD (Fig. 1). No patients with F0 fibrosis had T2DM, but 80% had NGT. On the other hand, the prevalence of

NGT in the patients with F3 fibrosis was only 21.6%, and the prevalence of T2DM was 48.6%. In accordance with the progression of hepatic fibrosis, the prevalence of patients with T2DM was significantly increased and that of NGT was significantly decreased. T2DM is reportedly an independent predictor for the progression of hepatic fibrosis in patients with NAFLD [10]. Our data also indicated that the development of T2DM might induce the development of hepatic fibrosis in patients with NAFLD. On the other hand, however, the presence of NASH and NAFLD themselves is reportedly associated with a high risk of developing T2DM [12].

According to the clinical and physiological data of the four groups of patients with NAFLD (Table 1), age, aspartate aminotransferase, hepatic fibrosis markers, and ferritin were higher and platelets were lower in accordance with the progression of hepatic fibrosis, as previously reported [8,23]. To clarify the

**Table 4. Comparison of variable parameters of continuous glucose monitoring between patients with mild fibrosis (F0–2) and severe fibrosis (F3–4).**

Variable	Mild fibrosis (F0-2)		Severe fibrosis (F3-4)		P value
Average median blood glucose (mg/dl)	108.1	± 12.2	131.5	± 34.3	<0.00001
Average standard deviation (mg/dl)	17.4	± 5.2	39.7	± 17.8	0.0022
Minimum blood glucose (mg/dl)	81.7	± 28.7	72.5	± 26.4	0.9221
Maximum blood glucose (mg/dl)	118.8	± 12.5	237.5	± 65.1	0.0019
ΔMin–max blood glucose (mg/dl)	115.2	± 22.8	165.0	± 69.6	0.0029

Average median blood glucose: average median glucose of the patients during the 24-hour monitoring period.

Average standard deviation: average standard deviation of blood glucose of the patients during the 24-hour monitoring period.

Minimum and maximum blood glucose values: lowest and highest values, respectively, during the 24-hour monitoring period.

ΔMin–max blood glucose: difference between minimum and maximum blood glucose. Data are expressed as median ± standard deviation.

doi:10.1371/journal.pone.0076161.t004

detailed glucose impairment related to the progression of hepatic fibrosis, we evaluated the various parameters of glucose metabolism. HbA1c was gradually elevated with the progression of hepatic fibrosis (Fig. 2A). Although HbA1c in the patients with F3 fibrosis was higher than that in the patients with F0 fibrosis, HbA1c in all fibrosis groups was around 6.0% because the glucose impairment in all patients in this study was mild enough to perform the 75gOGTT. On the other hand, 1,5-AG remarkably gradually decreased in accordance with the progression of hepatic fibrosis (Fig. 2B). Considering both the results of HbA1c and those of 1,5-AG, evaluation of 1,5-AG might more closely reflect the glycemic variability in patients with NAFLD, and glycemic variability would be closely related to the progression of hepatic fibrosis. IR is considered to be one of the most important predictive factors for the development of NAFLD and NASH [11]. Therefore, evaluation of HOMA-IR also was investigated in our study. HOMA-IR also gradually increased in accordance with the progression of hepatic fibrosis (Fig. 2C). However, the insulinogenic index, the ability of early insulin secretion, was not significantly different among the groups (Fig. 2D).

We next investigated and evaluated the clinical features of 75gOGTT in patients with NAFLD in relation to the progression of hepatic fibrosis (Fig. 3). After oral glucose loading, glucose levels were increased in the patients with advanced fibrosis (F3) compared with the patients with mild fibrosis (F0–2) (F3 versus F0,  $P<0.01$ ; F3 versus F1,  $P<0.001$ ; F3 versus F2,  $P<0.05$  at 60 minutes) (Fig. 3A). The elevation of glucose levels continued until 120 minutes after oral glucose loading in the patients with F3 fibrosis. In addition, the AUC-PG as the marker for total glucose secretion after oral glucose loading also significantly gradually increased in accordance with the progression of hepatic fibrosis (F0 versus F2,  $P<0.05$ ; F0 versus F3,  $P<0.01$ ; F1 versus F2,  $P<0.05$ ; F2 versus F3,  $P<0.05$ ) (Fig. 3B). Furthermore, f-IRI was significantly elevated in accordance with the progression of hepatic fibrosis (F0 versus F2,  $P<0.05$ ; F0 versus F3,  $P<0.05$ ; F1 versus F2,  $P<0.05$ ; F1 versus F3,  $P<0.001$ ) (Fig. 3C). These results are agreement with the results in Figure 2C. After oral glucose loading, insulin secretion was relatively quickly elevated in all groups of patients with NAFLD. Insulin secretion levels at 30 minutes were not statistically different among the groups. This result is in agreement with the results of the insulinogenic index (Fig. 2D). The insulin secretion in the mild fibrosis group (F0 and F1) decreased relatively early with the decrease in blood glucose levels. On the other hand, insulin secretion in the advanced fibrosis groups continued until 120 minutes. Therefore, the insulin levels at 120 minutes were remarkably higher in the patients with advanced hepatic fibrosis (F0 versus F2,  $P<0.05$ ; F0 versus F3,  $P<0.01$ ; F1 versus F2,  $P<0.01$ ; F1 versus F3,  $P<0.01$ ), as previously reported [24,25]. Furthermore, the AUC-IRI was also significantly increased in accordance with the progression of hepatic fibrosis (F0 versus F3,  $P<0.05$ ; F1 versus F3,  $P<0.01$ ) (Fig. 3D). It is known that insulin has the potential to function as a growth factor. IR and/or T2DM reportedly may accelerate the progression of NASH through lipogenesis, inflammation, and fibrogenesis [26] and induce cancer growth [27]. Kaji et al. also reported that not only glucose and insulin alone, but also a combination of the two, stimulated the proliferation and activation of hepatic stellate cells. They concluded that the IR status directly accelerates the development of hepatic fibrosis and hepatocarcinogenesis through activation of hepatic stellate cells [28]. Taken together with our results, hyperinsulinemia and hyperglycemia might be related to the progression of hepatic fibrosis in NAFLD.

To elucidate the predictive factors that are associated with the development of hepatic fibrosis in NAFLD, various parameters of

glucose metabolism were compared between the mild fibrosis group (F0–2) and severe fibrosis group (F3). In univariate analysis (Table 2), age ( $P=0.00967$ ), body mass index ( $P=0.01395$ ), HbA1c ( $P=0.0452$ ), f-IRI ( $P=0.00012$ ), HOMA-IR ( $P=0.0032$ ), AUC-IRI ( $P=0.00103$ ), and AUC-PG ( $P=0.01093$ ) were significantly higher and 1,5-AG ( $P=0.00014$ ) was significantly lower in the severe fibrosis group than in the mild fibrosis group (Table 1, Figs. 2 and 3). As determined by multivariate logistic regression analysis, only 1,5-AG ( $P=0.008$ ; Z value,  $-2.65$ ; OR, 0.89509; 95% CI, 0.82473–0.97145) remained as the independently associated factor for advanced fibrosis (Table 3). As mentioned in the above results, it was considered that 1,5-AG might have reflected the glycemic variability in patients with NAFLD in this study.

To confirm the relationship between glycemic variability and progression of hepatic fibrosis in NAFLD, the changes in blood glucose levels during 24 hours were monitored by the CGMS in the patients with NAFLD with severe fibrosis (F3–4,  $n=10$ ) and mild fibrosis (F0–2,  $n=10$ ). CGMS examinations were performed at the inpatient center of Kochi Medical School, and the timing of meals and calories contained in the meals were strictly standardized during the examination. In this study, the severe fibrosis group (F3–4,  $n=10$ ) included three patients with LC (F4) who were all diagnosed with T2DM and whose hyperglycemia was too high to perform the 75gOGTT. However, none of the patients in this study took any anti-diabetic drugs or insulin injections. Figure 4 shows that the variability of the median glucose levels of the patients with mild fibrosis (F0–2) was remarkably smaller than that of the patients with severe fibrosis (F3–4). Furthermore, the standard deviation in severe fibrosis ( $39.7\pm 17.8$  mg/dl) was much larger than that in mild fibrosis ( $17.4\pm 5.2$  mg/dl,  $P=0.0022$ ) (Table 4). Although the minimum blood glucose levels in patients with severe fibrosis tended to be lower than those in patients with mild fibrosis ( $72.5\pm 26.4$  versus  $81.7\pm 28.7$  mg/dl,  $P=0.9221$ ), the maximum blood glucose level in patients with severe fibrosis was remarkably higher than that in patients with mild fibrosis ( $237.5\pm 65.1$  versus  $118.8\pm 12.5$  mg/dl,  $P=0.0019$ ) (Table 4). As a result, the  $\Delta$ Min–max blood glucose was also significantly larger in severe fibrosis than in mild fibrosis ( $165.0\pm 69.6$  versus  $115.2\pm 22.8$  mg/dl,  $P=0.0029$ ). The shadowed areas, which indicate glucose levels, were statistically different between the mild and severe fibrosis groups showed postprandial hyperglycemia, and the hyperglycemias were long continued (Fig. 4). Moreover, we noticed a specific clinical feature of postprandial hyperglycemia in patients with NAFLD. The peaks of postprandial hyperglycemia occurred 1 hour after every meal. Interestingly, glucose levels from midnight to early morning tended to be lower in patients with severe fibrosis and had become elevated by breakfast. The statistical differences in these parameters between the mild and severe fibrosis groups did not change even when three patients with LC (F4) were excluded from the severe fibrosis group (Figure S1 and Tables S2 and S3 in File S1). Moreover, in chronic hepatitis C, even in liver cirrhosis, the changes in blood glucose didn't necessarily show any certain patterns unlike NAFLD (data not shown). Taken together with our results, severe variability of blood glucose changes might be closely related to the progression of hepatic fibrosis in NAFLD.

Postprandial hyperglycemia and glycemic variability are reportedly involved in the progression of atherosclerosis through an increase in oxidative stress, activation of inflammatory cytokines and inflammation [13–15], and induction of other pathogenic complications [29,30,31]. In addition, repetitive postprandial glucose fluctuation reportedly evokes more pronounced adhesion of monocytes to endothelial cells compared with



that induced by stable hyperglycemia [32]. In addition, the main mechanism of monocyte adhesion to endothelial cells has been shown to be increased serum adrenaline induced by postprandial glucose spikes [33]. Furthermore, the importance of glucose variability was recently recognized as an independent factor associated with increasing mortality in patients with diabetes [34,35] and critically ill patients [36,37]. Oxidative stress is well known as one of most important factors for inflammation and progression of hepatic fibrosis in NAFLD [16,17]. Taken together with our results, therefore, variability of blood glucose might also induce monocyte adhesion to endothelial cells, activate inflammatory cytokines and inflammation, and increase oxidative stress in the liver of patients with NAFLD.

There are several limitations of this study. We showed that the prevalence of patients with T2DM was significantly increased (Fig. 1) and age and BMI tended to increase (Table 1) in accordance with the progression of hepatic fibrosis. It is known that age and BMI contribute to both the prevalence of T2DM and the progression of hepatic fibrosis. Therefore, not only progression of T2DM, but also age and BMI, might have influenced the progression of hepatic fibrosis in this study.

In conclusion, we clarified that hyperinsulinemia and hyperglycemia are important predictive factors for the development of hepatic fibrosis in this study. More importantly, variability of blood glucose is one of most important predictive factors in glucose impairment for progression of hepatic fibrosis in NAFLD. Therefore, we might need to reconsider the use of anti-diabetic drugs to inhibit the progression of hepatic fibrosis during treatment of patients with NAFLD.

## Supporting Information

**File S1 Supplemental Figures and Tables. Figure S1, Twenty-four-hour sensor glucose profiles by continuous glucose monitoring system.** The changes in the median sensor glucose levels during 24 hours are shown in the patients with A) F0–2 fibrosis ( $n=10$ ) and B) F3 fibrosis ( $n=7$ ). The variability of median glucose levels among the patients with F0–2 fibrosis was remarkably smaller than that among the patients with F3 fibrosis. Median glucose levels in the patients with F3 fibrosis were higher than those with F0–2 fibrosis (shadows areas,  $P<0.05$  to  $P<0.001$ ): Time of meal consumption. **Table S1, Comparison of the clinical and physiological characteristics**

**between the patients with mild fibrosis (F0–2) and severe fibrosis (F3–4).** Data are expressed as median  $\pm$  standard deviation. BMI, body mass index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyl transpeptidase; ChE, cholinesterase; T-Cho, total cholesterol; TG, triglycerides; FPG, fasting plasma glucose; Plt, platelets; Fe, plasma iron; HA, hyaluronic acid; IV collagen 7S, type IV collagen 7S; P-3-P, type III procollagen N-peptide. **Table S2, Comparison of the clinical and physiological characteristics between the patients with F0–2 fibrosis and F3 fibrosis.** Data are expressed as median  $\pm$  standard deviation. BMI, body mass index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyl transpeptidase; ChE, cholinesterase; T-Cho, total cholesterol; TG, triglycerides; FPG, fasting plasma glucose; Plt, platelets; Fe, plasma iron; HA, hyaluronic acid; IV collagen 7S, type IV collagen 7S; P-3-P, type III procollagen N-peptide. **Table S3, Comparison of variable parameters of continuous glucose monitoring between patients with F0–2 fibrosis and F3 fibrosis.** Average median blood glucose: average median glucose of the patients during the 24-hour monitoring period. Average standard deviation: average standard deviation of blood glucose of the patients during the 24-hour monitoring period. Minimum and maximum blood glucose values: lowest and highest values, respectively, during the 24-hour monitoring period  $\Delta$ Min–max blood glucose: difference between minimum and maximum blood glucose. Data are expressed as median  $\pm$  standard deviation. (DOCX)

## Acknowledgments

Contributions: All listed authors contributed intellectually to the work presented here either through study concept and design, data acquisition, data analysis and interpretation, critical revision of the manuscript for important intellectual content; statistical analysis; funding or study supervision.

## Author Contributions

Conceived and designed the experiments: MO HH Y. Ikeda KC TS. Performed the experiments: MH MO HH Y. Ikeda RY Y. Ishikawa Y. Nagata K. Munekage TO AH Y. Nozaki-Fujimura NO. Analyzed the data: K. Masuda SN NS. Wrote the paper: MH MO.

## References

- Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, et al (1999) Nonalcoholic fatty liver diseases: a spectrum of clinical and pathological severity. *Gastroenterology* 116: 1413–1419.
- Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, et al (2009) Long-term follow-up of patients with nonalcoholic fatty liver. *Clin Gastroenterol Hepatol* 7: 234–238.
- Ono M, Saibara T (2006) Clinical features of nonalcoholic steatohepatitis in Japan: evidence from literature. *J Gastroenterol* 41: 725–732.
- Reddy SK, Steel JL, Chen HW, DeMateo DJ, Cardinal J, et al (2012) Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. *HEPATOLOGY* 55: 1809–1819.
- Chituri S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, et al (2002) NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. *HEPATOLOGY* 35: 373–379.
- Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, et al (2003) Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. *HEPATOLOGY* 37: 917–923.
- Angulo P (2002) Nonalcoholic fatty liver disease. *N. Engl. J. Med.* 18: 1221–1231.
- Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Arida A, et al (2010) Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. *HEPATOLOGY* 52: 913–924.
- Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A, et al (2008) Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. *HEPATOLOGY* 48: 792–798.
- Hossain N, Afendy A, Stepanova M, Nader F, Srishord M, et al (2009) Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. *Clin. Gastroenterol. Hepatol.* 7: 1224–1229.
- Sonsuz A, Basaranoglu M, Bilir M, Turk H, Akin P (2002) Hyperinsulinemia in nondiabetic, both obese and nonobese patients with nonalcoholic steatohepatitis. *Am. J. Gastroenterol.* 97: 495.
- Angulo P (2007) Obesity and nonalcoholic fatty liver disease. *Nutr. Rev.* 65: S57–63.
- Cerullo A, Esposito K, Piconi L, Ihnat MA, Thorpe JE, et al (2008) Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. *Diabetes.* 57: 1349–1354.
- Node K, Inoue T (2009) Postprandial hyperglycemia as an etiological factor in vascular failure. *Cardiovasc Diabetol.* 8: 23.
- Monnier L, Mas E, Ginot C, Michel F, Villon L, et al (2006) Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. *JAMA.* 295: 1681–1687.
- Hirose A, Ono M, Saibara T, Nozaki Y, Masuda K, et al (2007) Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. *HEPATOLOGY.* 45: 1375–1381.
- Fujii H, Kawada N (2012) Inflammation and fibrogenesis in steatohepatitis. *J Gastroenterol.* 47: 215–225.
- Klonoff DC (2005) Continuous glucose monitoring: roadmap for 21st century diabetes therapy. *Diabetes Care.* 28: 1231–1239.

19. Bialasiewicz P, Pawlowski M, Nowak D, Loba J, Czupryniak L (2009) Decreasing concentration of interstitial glucose in REM sleep in subjects with normal glucose tolerance. *Diabetic Medicine*. 26: 339–344.
20. Whalan DJ (1975) The ethics and morality of clinical trials in man. *Med. J. Aust.* 19: 491–494.
21. Brunt EM (2001) Nonalcoholic steatohepatitis: definition and pathology. *Semin Liver Dis* 21: 3–16.
22. Koschinsky T, Heinemann L (2001) Sensors for glucose monitoring: technical and clinical aspects. *Diabetes/Metabolism Research and Reviews* 17: 113–123.
23. Yoneda M, Fujii H, Sumida Y, Hyogo H, Itoh Y, et al (2011) Japan Study Group of Nonalcoholic Fatty Liver Disease. Platelet count for predicting fibrosis in nonalcoholic fatty liver disease. *J Gastroenterol.* 46: 1300–1306.
24. Kimura Y, Hyogo H, Ishitobi T, Nabeshima Y, Arihiro K, et al (2011) Postprandial insulin secretion pattern is associated with histological severity in non-alcoholic fatty liver disease patients without prior known diabetes mellitus. *J Gastroenterol Hepatol.* 26: 517–522.
25. Manchanayake J, Chitturi S, Nolan C, Farrell GC (2011) Postprandial hyperinsulinemia is universal in non-diabetic patients with nonalcoholic fatty liver disease. *J Gastroenterol Hepatol.* 26: 510–516.
26. Ota T, Takamura T, Kurita S, Matsuzawa N, Kita Y, et al (2007) Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. *Gastroenterology.* 132: 282–293.
27. Starley BQ, Calcagno CJ, Harrison SA (2010) Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. *HEPATOLOGY.* 51: 1820–1832.
28. Kaji K, Yoshiji H, Kitade M, Ikenaka Y, Noguchi R, et al (2008) Impact of insulin resistance on the progression of chronic liver diseases. *Int J Mol Med.* 22: 801–808.
29. Kilpatrick ES, Rigby AS, Atkin SL (2006) The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. *Diabetes Care.* 29: 1486–1490.
30. Hirsch IB, Brownlee M (2005) Should minimal blood glucose variability become the gold standard of glycemic control? *J Diabetes Complications.* 19: 178–181.
31. Kilpatrick ES, Rigby AS, Atkin SL (2010) For debate. Glucose variability and diabetes complication risk: we need to know the answer. *Diabet Med.* 27: 868–871.
32. Watada H, Azuma K, Kawamori R (2007) Glucose fluctuation on the progression of diabetic macroangiopathy—new findings from monocyte adhesion to endothelial cells. *Diabetes Res Clin Pract.* 77 Suppl 1: S58–61.
33. Jin WL, Azuma K, Mita T, Goto H, Kanazawa A, et al (2011) Repetitive hypoglycaemia increases serum adrenaline and induces monocyte adhesion to the endothelium in rat thoracic aorta. *Diabetologia.* 54: 1921–1929.
34. Monnier L, Colette C (2008) Glycemic Variability. Should we and can we prevent it? *Diabetes Care.* 31, suppl 2: S150–154.
35. Ceriello A, Inta MA (2010) Glycaemic variability: A new therapeutic challenge in diabetes and the critical care setting. *Diabetes UK. Diabetic Medicine.* 27: 862–867.
36. Egi M, Bellomo R, Stachowski E, French CJ, Hart G (2006) Variability of blood glucose concentration and short-term mortality in critically ill patients. *Anesthesiology.* 195: 244–252.
37. Pisarchik AN, Pochepen ON, Pisarchyk LA (2012) Increasing blood glucose variability is a precursor of sepsis and mortality in burned patients. *PLoS One.* 7: e46582.

# Aromatase-null mice expressing enhanced green fluorescent protein in germ cells provide a model system to assess estrogen-dependent ovulatory responses

Katsumi Toda · Yoshihiro Hayashi ·  
Atsuko Yamashita · Masaru Okabe ·  
Masafumi Ono · Toshiji Saibara

Received: 30 May 2013 / Accepted: 15 November 2013  
© Springer Science+Business Media Dordrecht 2013

**Abstract** Enhanced green fluorescent protein (EGFP) has provided us with valuable approaches for tracking living cells. We established a novel line of transgenic mice, which express EGFP in the testis and ovary. Histological analysis demonstrated that spermatids in the testis and oocytes in ovarian follicles beyond preantral stages were positive for EGFP. By exploiting these features, we evaluated ovulatory responses of aromatase-gene (*Cyp19a*) knockout mouse expressing the EGFP transgene, which is totally anovulatory due to 17 $\beta$ -estradiol (E2) deficiency. Ovulation in the knockout mice was induced by sequential injections of E2 on days 1, 4 and 5, pregnant mare serum gonadotropin on day 4 and human chorionic gonadotropin on day 6. Fluorescent oocytes were readily detectable at 15 h after

the last gonadotropin injection in the oviduct under a fluorescence stereomicroscope, even when only one oocyte was present. However, when E2 supplementation on day 4 or day 5 in the regimen was omitted, no ovulated oocytes were detected, indicating that exogenous E2 supplementation at the time of gonadotropin stimulation is necessary to induce ovulation in aromatase-gene knockout mice. Our results further demonstrated that the current mouse line can provide an alternative tool to study germ cell biology, including oogenesis, ovulation and senescence.

**Keywords** Aromatase-knockout mouse ·  
Ovulation · Estrogen · Enhanced green  
fluorescent protein

K. Toda (✉)  
Department of Biochemistry, School of Medicine, Kochi  
University, Nankoku, Kochi 783-8505, Japan  
e-mail: todak@kochi-u.ac.jp

Y. Hayashi  
Department of Pathology, School of Medicine, Kochi  
University, Nankoku, Kochi 783-8505, Japan

A. Yamashita · M. Okabe  
Genome Information Research Center, Research Institute  
for Microbial Diseases, Osaka University, Yamadaoka  
3-1, Suita, Osaka 565-0871, Japan

M. Ono · T. Saibara  
Department of Gastroenterology and Hepatology, School  
of Medicine, Kochi University, Nankoku,  
Kochi 783-8505, Japan

## Introduction

Ovulation is a vital step for natural reproductive activity in females. It is well established that the ovulatory process is regulated by various hormones and signaling molecules (Richards 1994; Barnett et al. 2006; Drummond and Fuller 2012). We noted during ovulatory stimulation experiments that oocytes released from the ovary were not always localized in the ampulla of the oviduct. Furthermore, inaccurate estimations of ovulatory efficacy might occur when genetically manipulated mice with ovulatory impairment were employed in studies. An aromatase-deficient mouse, in which estrogen synthesis is impaired (Fisher et al. 1998; Toda et al.

2001), is such a mutant mouse with ovulatory impairment. Mouse models that facilitate detection of the ovulatory responses are highly supportive of the quantitative assessment of such responses. Enhanced green fluorescent protein (EGFP) has been used as a genetically encoded fluorescence marker owing to its autocatalytic formation of the chromophore (Tsien 1998). This protein has provided us with valuable approaches in live cell imaging, including the tracking of GFP-labeled living cells in tissues. In fact, we generated a mouse line expressing EGFP in an estrogen-dependent manner in restricted tissue sites (Toda et al. 2004) and employed it as a biosensor to assess the estrogenic activity of endocrine-disturbing chemicals (Toda et al. 2005). During the generation of EGFP-mouse lines showing expression patterns different from the previous line, a few transgenic lines were selected owing to their characteristic expression of EGFP, namely, expression of the transgene in oocytes in females. Here, we report characterization of one of the transgenic mouse lines that we obtained and its application for evaluation of the ovulatory responses of aromatase-deficient mice.

## Materials and methods

### Animal care

Animal experiments were carried out according to the guidelines of institutional animal regulations. All animals were maintained on a 12 h light/dark cycle at 22–25 °C and given water and phytoestrogen-low rodent chow (NIH-07PLD, Oriental Yeast Ltd., Tokyo, Japan) ad libitum. The aromatase gene (*Cyp19a*) was disrupted by homologous recombination (Toda et al. 2001). The genetic background for the present study was a mixture of C56BL/6j and BDF1.

### Generation and selection of EGFP transgenic mice

The structure of the EGFP transgene employed in the present study was schematically presented in Fig. 1a. The transgene (2 kbp) consists of the estrogen-responsive element (ERE) of the *Xenopus laevis* A2 vitellogenin gene and a minimal promoter of the mouse heat shock protein (HSP) 68 gene linked to the EGFP coding sequence and SV40 polyadenylation sequence. A DNA fragment containing the ERE (underlined in the sequence), 5'-TCTAGAGGTCACAGTGACCTGAA

GTTAATGTAACCTCATCTAGA-3' was prepared by digestion of pERETKLuc plasmid DNA (a gift from Prof. MG Parker) (Mak et al. 1999) with *Xba*I. The fragment was inserted into *Eco*RV/*Nde*I-digested pnestinhsp68EGFP (Kawaguchi et al. 2001). Transgenic mice were generated according to the method as described (Hogan et al. 1994). A purified DNA fragment obtained by digestion of the transgene vector with *Sal*II and *Sca*I was injected into fertilized eggs of a mouse strain, BDF1, which was generated by crossing between female C57BL/6 and male DBA/2. The manipulated eggs were transferred into foster mothers. A total of 59 pups (34 male and 25 female pups) were obtained. The 59 founders were outcrossed with C57BL6/J to yield F1 offspring. Transmission of the transgene was examined by PCR analysis using tail DNA with the following primers: P1-EGFP, 5'-GAGCTGGACGGCGACGTA AAC-3'; and P2-EGFP, 5'-CACCTTGATGCCGTTCTTCTGC-3' (Toda et al. 2004), and the expression of EGFP was determined by observation of tissues from the F1 offspring under a fluorescence stereomicroscope. These analyses identified 12 founders that transmitted a functional EGFP gene. Mice of the selected line were crossed repeatedly with mice heterologous for the *Cyp19a* locus to produce aromatase (*Cyp19a*)-deficient mice carrying the EGFP transgene. In this report, we hereafter refer to the wild-type mice with the EGFP transgene and mice lacking the functional *Cyp19a* with the transgene as Ar<sup>+/+</sup> mice and Ar<sup>-/-</sup> mice, respectively.

### Total genomic Southern blot analysis and copy number estimation of the EGFP gene

Genomic DNA (20 µg) from the tail of mouse line C41 was cleaved to completion with either *Bam*HI or *Pst*I and electrophoresed on a 0.8 % agarose gel. The DNA fragments were then transferred to a nylon membrane filter and the filter was hybridized with the <sup>32</sup>P-radiolabeled cDNA fragment coding for EGFP. In order to estimate copy numbers of the transgene integrated into the mouse genome, the coding region of the EGFP gene was amplified by PCR with P1-EGFP and P2-EGFP primers using the genomic DNA of the transgenic mouse and known amounts of the transgene used for microinjection. The amounts of the PCR products from the tail DNA were compared to those from known amounts of the transgene to calculate approximate copy numbers in the genome.